Zonisamide and Topiramate Interaction

Drug interaction information between Zonisamide and Topiramate.

Zonisamide and Topiramate have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Zonisamide and Topiramate. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Zonisamide

Anticonvulsant (Sulfonamide)

Drug B

Topiramate

Anticonvulsant

How They Interact

Both drugs block the same enzyme, which can make your blood too acidic. This combination also makes it more likely that you will develop kidney stones.

FDA Label Information

7.2 Other Carbonic Anhydrase Inhibitors Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide or acetazolamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation.

Frequently Asked Questions

What SPL severity band is on file for Zonisamide + Topiramate?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Topiramate has 30 labeled pairs on file vs Zonisamide's 13. In the moderate band specifically: Zonisamide has 3 (also Alogliptin, Ertugliflozin); Topiramate has 3 (also Alogliptin, Ertugliflozin).

What mechanism field is on file for Zonisamide and Topiramate?

Both drugs block the same enzyme, which can make your blood too acidic. This combination also makes it more likely that you will develop kidney stones.

Topiramate's labeled portfolio outnumbers Zonisamide

SPL source-record counts only. This page's band is moderate · classes on file: Zonisamide (Anticonvulsant (Sulfonamide)); Topiramate (Anticonvulsant).

Zonisamide

0 major · 3 moderate · 10 minor · 13 total

Topiramate

0 major · 3 moderate · 27 minor · 30 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.